Inactive Instrument
Allied Corp. Stock Other OTC
Stocks
ALID
US0191141078
Pharmaceuticals
OTC Markets Traded| Market Cap | 1.3M 1.15M 1.06M 986K 1.85M 123M 1.88M 12.66M 4.9M 60.64M 4.9M 4.79M 211M | P/E 2023 |
-2.13x | P/E 2024 | -2.52x |
|---|---|---|---|---|---|
| Enterprise Value | 7.55M 6.63M 6.11M 5.71M 10.72M 713M 10.91M 73.32M 28.4M 351M 28.36M 27.74M 1.22B | EV / Sales 2023 |
394,366,816x | EV / Sales 2024 | 171,944,593x |
| Free-Float |
52.84% | Yield 2023 * |
-
| Yield 2024 | - |
| 1 day | -5.00% |
| Manager | Title | Age | Since |
|---|---|---|---|
| Director of Finance/CFO | - | - | |
Radka Milanova
CTO | Chief Tech/Sci/R&D Officer | 71 | - |
James Smeeding
PRN | Corporate Officer/Principal | - | 2020-05-01 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | - | - | |
James Smeeding
BRD | Director/Board Member | - | 2020-05-01 |
Abdul Nnyenje
BRD | Director/Board Member | - | 2024-10-20 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -5.00% | -5.00% | - | - | 117 | ||
| +2.95% | -4.15% | +298.54% | +10.81% | 2.46B | ||
| +0.24% | -15.64% | +134.07% | +115.70% | 1.63B | ||
| -1.26% | -10.27% | -14.79% | +128.62% | 462M | ||
| -4.00% | -2.04% | +17.07% | -20.00% | 53.64M | ||
| Average | -1.41% | -5.08% | +108.72% | +58.78% | 1.15B | |
| Weighted average by Cap. | +1.49% | -7.22% | +205.52% | +59.47% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 0.07 0.06 0.06 0.05 0.1 6.8 0.1 0.7 0.27 3.35 0.27 0.26 11.65 | 0.1 0.08 0.08 0.07 0.14 9.08 0.14 0.93 0.36 4.47 0.36 0.35 15.55 |
| Net income | -10.68M -9.38M -8.64M -8.08M -15.15M -1.01B -15.43M -104M -40.15M -497M -40.09M -39.21M -1.73B | -3.98M -3.49M -3.22M -3.01M -5.64M -375M -5.75M -38.61M -14.95M -185M -14.93M -14.6M -643M |
| Net Debt | 5.65M 4.96M 4.57M 4.28M 8.02M 533M 8.17M 54.88M 21.26M 263M 21.22M 20.76M 914M | 6.25M 5.49M 5.06M 4.73M 8.87M 590M 9.03M 60.66M 23.5M 291M 23.46M 22.95M 1.01B |
Employees
-
Sector
Pharmaceuticals
















